Novo Nordisk A/S - Share repurchase programme On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount of up to DKK 1.7 billion in the period from 15 August 2008 to 19 December 2008. Since the announcement as of 27 October 2008, the following transactions have been made under the programme: Number of Average Transaction shares purchase price value, DKK Accumulated, last announcement 2,838,500 793,731,994 27 October 2008 50,000 276.2150 13,810,750 28 October 2008 50,000 280.4600 14,023,000 29 October 2008 50,000 289.5500 14,477,500 30 October 2008 50,000 305.6500 15,282,500 31 October 2008 50,000 306.6800 15,334,000 Accumulated under the programme 3,088,500 866,659,744 Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 68,920 B-shares in the period from 27 October 2008 to 31 October 2008. The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 24,232,540 treasury shares, corresponding to 3.8% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 E-mail: ekh@novonordisk.com E-Mail: mlau@novonordisk.com Hans Rommer Tel: (+45) 4442 4765 E-mail: hrmm@novonordisk.com In North America: Kasper Roseeuw Paousen Sean Clements Tel: (+45) 4442 4471 Tel: (+1) 609 514 8316 E-mail: krop@novonordisk.com E-mail: secl@novonordisk.com Company Announcement no 70 / 2008